Aldeyra Therapeutics (ALDX) Q2 2026 earnings summary

Executive summary

• Focused on developing therapies for immune-mediated diseases, with late-stage candidates reproxalap (dry eye disease) and ADX-2191 (retinal diseases).

• No products approved or commercialized; revenue depends on regulatory approval and successful commercialization of reproxalap.

• AbbVie holds an exclusive option for co-development and commercialization of reproxalap, but has not exercised it as of August 6, 2026.

Financial highlights

• Net loss for Q2 2026 was $5.5 million, down from $9.8 million in Q2 2025; six-month net loss was $8.9 million, down from $19.7 million year-over-year.

• Research and development expenses decreased 59% year-over-year for Q2 and 63% for the six months, mainly due to lower clinical and manufacturing costs.

• General and administrative expenses increased 42% in Q2 but decreased 25% for the six months, reflecting higher personnel and legal costs in Q2 but lower personnel costs overall.

• Cash and cash equivalents were $45.1 million as of June 30, 2026, down from $70.0 million at year-end 2025.

• Total stockholders' equity was $37.9 million as of June 30, 2026.

Outlook and guidance

• Cash and cash equivalents expected to fund operations into the second half of 2028, excluding potential licensing or product revenue.

• Additional funding will be needed for full development, regulatory, and commercialization activities.

• Awaiting further FDA feedback on reproxalap NDA resubmission; future regulatory requirements may impact timelines and costs.